Free tool
FAERS Monitor: Mircera
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125164 or its brand name (Mircera, Methoxy Polyethylene Glycol-Epoetin Beta). Reports on generic versions are filed under their own applications.
Reports
11,052
Serious
7,930
72% of reports
Hospitalization
2,987
Death reported
2,926
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug hypersensitivity3,003
- death1,583
- dyspnoea1,139
- nausea825
- pruritus783
- vomiting684
- haemoglobin decreased587
- flushing515
- unresponsive to stimuli356
- anaemia347
- feeling hot341
- no adverse event316
- dizziness298
- hypotension283
- rash276
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 44 |
| 2009 | 137 |
| 2010 | 192 |
| 2011 | 245 |
| 2012 | 778 |
| 2013 | 1,001 |
| 2014 | 441 |
| 2015 | 682 |
| 2016 | 512 |
| 2017 | 559 |
| 2018 | 686 |
| 2019 | 1,443 |
| 2020 | 631 |
| 2021 | 494 |
| 2022 | 691 |
| 2023 | 874 |
| 2024 | 894 |
| 2025 | 540 |
| 2026 | 208 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,107 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 3,003 | 30.0 | 29.1 | 83,563 |
| unresponsive to stimuliSignal | 356 | 26.6 | 24.0 | 8,636 |
| haemoglobin decreasedSignal | 587 | 10.9 | 10.1 | 5,285 |
| feeling hotSignal | 341 | 10.6 | 9.6 | 2,960 |
| flushingSignal | 515 | 9.7 | 8.9 | 4,001 |
| pruritusSignal | 783 | 3.9 | 3.6 | 1,701 |
| dyspnoeaSignal | 1,139 | 3.8 | 3.6 | 2,445 |
| deathSignal | 1,583 | 3.5 | 3.3 | 2,942 |
| anaemiaSignal | 347 | 3.5 | 3.1 | 611 |
| no adverse eventSignal | 316 | 3.3 | 3.0 | 514 |
| vomitingSignal | 684 | 2.8 | 2.6 | 789 |
| hypotensionSignal | 283 | 2.7 | 2.4 | 301 |
| nausea | 825 | 2.0 | 1.9 | 417 |
| rash | 276 | 1.2 | 1.1 | 10 |
| dizziness | 298 | 1.1 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.